IACRN and ACRES Form Global Research Alliance
IACRN and ACRES have created a strategic alliance agreement.
The International Association of Clinical Research Nurses (IACRN) and the Alliance for Clinical Research Excellence and Safety (ACRES) have created a strategic alliance agreement, setting the stage for multiple collaborative projects.
The two organizations will work together to identify the clinical research nurse workforce worldwide, to develop and conduct initiatives focused on evidence-based best practices in clinical research nursing and to co-develop and present at key conferences. Also, ACRES will provide representation and expertise for clinical research nursing in initiatives aimed at establishing research site standards.
“Clinical research obviously has a global reach,” noted Liza Behrens, current President of IACRN, “and while our nurse members bring passion and expertise in enhancing the quality and safety to clinical research through the use of specialty nursing practices, this alliance with ACRES will definitely widen and positively impact clinical research practices throughout the world.”
IACRN’s main aim is to enhance clinical research quality and safety through specialized nursing practice by defining, validating and advancing clinical research nursing as a specialty practice as well as by supporting the professional development of registered nurses who directly or indirectly impact the care of clinical research participants.
On the other hand, ACRES seeks to collaboratively leverage the expertise and investments of research stake-holders world-wide to build and maintain a global system for clinical trials that are conducted according to the highest standards of safety, quality, and efficiency while aligning ethical principles with good business practices to benefit all peoples.
"The education, training, skills, commitment and judgment of all professionals in clinical research are keys to quality and safety, and none of these are more important than the role of professional research nurses. Our strategic relationship with IACRN will ensure that this important perspective is fully represented as ACRES allies work together to build a global system for clinical research that recognizes and rewards excellence worldwide," noted Dr. Honorio Silva, ACRES Vice-President for Professionalism and Systems Integration.
Read the full release here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
